Datatrial Limited
Datatrial is an eClinical solutions company, providing comprehensive data management, bio-statistical and consulting services. We have our own proprietary software, nowEDC™ which has been deployed globally in Phase I to Phase III trials. Our ethos is to collaborate with our customers to find and offer solutions that will assist in the achievement of clinical objectives.
Desktop Genetics
Desktop Genetics is a UK-based biotech software company dedicated to making commercial R&D more productive and cost efficient. We develop bespoke workflow tools to simplify the most time-consuming and frustrating challenges facing molecular biologists in genome-editing, disease biology, antibody engineering, cell line development, functional genomics and protein production.
Each tool comprises a collection of functional modules, powered by our proprietary DNA Search Engine technology. To date, modules have let users search for DNA sequences across the world, create an in-lab knowledge base with persistent DNA and oligo sequence data, automatically calculate optimal cloning strategies and repurpose existing DNA. Easily deployed with your existing DNA sequence databases, our technology streamlines and automates workflows so that your skilled personnel can focus on the critical research that drives your business.
Founded by scientists and researchers, our team is experienced with the technical, operational and financial challenges facing molecular biology laboratories today. We are fluent in the languages of biology, programming, and R&D operations, ensuring your needs are translated into a superior business and research tool. We look to partner with life science companies to deploy existing modules and develop new ones from the ground up. Get in touch with us today to discuss how we can help make your DNA work for you.
Contact: Victor Dillard, COO - victord@deskgen.com
Domainex
Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates already in clinic.
Domainex reduces industry average drug discovery timelines by as much as 30% through the application of novel proprietary technologies and a highly focussed and integrated approach to medicinal chemistry and computational chemistry. These technologies and Domainex’s approach also enable it to successfully tackle a greater range of drug target classes, such as kinases, proteases, ion channels, proteins involved in epigenetics and protein-protein interactions.
Domainex has applied its unique technologies and focussed discovery approach to enable it to develop its own pipeline of oncology drugs, including inhibitors of the kinases IKKε/TBK1 for both oncology and inflammation and a number of epigenetics related lysine methyltransferases, including G9a
Dr Eddy Littler
Chief Executive OfficerDr Joanne McCudden
Head of Business Developmente-therapeutics
e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company’s discovery and development activity is focused in cancer and disorders of the nervous system. The firm has two drugs in the clinic: ETS2101, which is in phase I trials for cancer; and ETS6103, which is in phase II trials for major depressive disorder. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.
Epistem Ltd
Epistem is a biotechnology company with a specialist understanding of epithelial tissue and stem cell analyses, operating three distinct business divisions.
The Contract Research Division delivers innovative preclinical research services in the areas of oncology (inc. leukaemia), mucositis, inflammatory bowel disease, rheumatoid arthritis, wound healing and skincare. Working with over 200 pharmaceutical, biotechnology, and personal care companies worldwide, it offers proprietary assays for target validation, screening, efficacy, and translational biology using some of the latest technology, including small animal imaging, and with a GCLP accredited histology suite.
The Personalised Medicine Division is committed to facilitating a more tailored approach to patient treatment and care. It applies innovative gene expression technology to discovering novel drug-induced biomarkers to GCLP standard. It has also developed Genedrive™, a ‘point of care’ molecular diagnostic device providing a ‘near patient’ diagnosis in less than 30 minutes using hand held apparatus.
Our Novel Therapies Division is identifying the key regulators (proteins and peptides) of epithelial stem cells with the aim of developing therapeutics to control cell production.
Dr Andrew Carnegie
Business Development ManagerMr Jeremy Kamaluddin
Business Development DirectorGlythera Ltd
Glythera is an emerging biotechnology company specializing in the development of next generation biotherapeutics through the application of its advanced proprietary conjugation and glycosylation technologies.
Located in the North East of the UK with its dedicated bioprocessing and chemistry development laboratories at Newcastle University, Glythera is positioned as a critical partner in any development program centred on its PermaLink™ and PermaCarb™ technologies.
Our PermaLink™ platform supports highly selective site specific conjugation whilst demonstrating significantly increased stability with our core focus being in the development of enhanced Antibody Drug Conjugates and bi-specifics.
Glythera’s PermaCarb™ technology allows direct substitution of endogenous glycan’s or correction of micro-heterogeneity using stable analogues to improve bioavailability and efficacy and has been demonstrated in a range of next generation biotherapeutics.
Our Mission is to enable improved clinical regimes through the creation of the next generation of safe, efficacious biotherapeutic products in oncology and therapeutic indications.
Dr David Simpson
Chief Operating OfficerHypha Discovery Ltd
Hypha collaborates with pharma/biotech and agrochemical groups in the following areas
1. Production of metabolites of clinical and preclinical stage compounds that are difficult to synthesise using metabolising microbes:
+ mg amounts for MetID, quantification standards
+ gram quantities for tox/pharmacological studies
+ includes glucuronides and chemically intractable hydroxyl derivatives
Our microbial biotransformation service is also used to improve PK/solubility in hit-to-lead compounds
2. Niche natural products hit-finding
Licensing access to Hypha's MycoDiverse natural products library.
+ Used by biotech and pharma to find hit compounds against "difficult-to-hit" targets
+ Molecular weight range mostly between 200 and 400 DA
+ 50% novelty
+ Exclusive rights to develop and commercialise
3. Fermentation and purification of small molecules for semi-synthetic lead optimisation
Dr Liam Evans
CEOIllingworth Research
Founded as Clinical Development & Support Services Ltd (CDSS) in 1998, Illingworth Research is a Clinical Research Organisation (CRO) providing a wide range of clinical development services to the pharmaceutical, healthcare, biotechnology and medical device industries. We are experts in the management of Phase I to IV clinical trials across many different therapeutic areas.
From our base in Cheshire UK, where we are co-located with our sister company ResearchNurses.co, we offer the ultimate clinical research outsourcing partnership for sponsors across the globe.
We have worked with all types of clients, from start-up biotechnology companies to large international pharmaceutical companies, providing strong sponsor/CRO partnerships to deliver a competitive advantage.
Mr Kieran Casey
Director Business DevelopmentMGB Biopharma
MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise.
Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens. Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.
MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections.
MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.
Dr Miroslav Ravic
Mr Raymond Spencer
MiNA Therapeutics
MiNA Therapeutics is a virtual biotechnology company pioneering the activation of gene expression with short activating RNA (saRNA).
Harnessing a proprietary algorithm, MiNA is developing a revolutionary class of therapeutics that activate key genes in major disease pathways. MiNA's ability to selectively activate master regulatory genes represents a new frontier in precision medicine.
MTL-501 is a saRNA liver cancer therapeutic that activates the CEBPA gene. Intravenous injection of MTL-501 in a liver cancer rat model reduced tumour burden by 80% whilst increasing significantly serum albumin. In vitro work has indicated the dramatic potential of CEBPA saRNA as a universal anti-cancer therapeutic in non-small cell lung, prostate, pancreas, leukaemia, lymphoma and glioblastoma. MTL-301 is a Type 1 diabetes therapeutic. In vitro work demonstrated glucose responsive insulin secretion by both CD34+ adult stem cells and HepG2 cells.